We confirmed significantly higher ketone body concentrations after dapagliflozin treatment, corresponding to the known increased risk of ketosis and diabetic ketoacidosis associated with SGLT2 inhibition [14]. Here, SLC5A2 is linked to diabetic ketoacidosis.